News

Zerlasiran and muvalaplin studies published

December 31, 2024

Results of Phase 2 studies of zerlasiran and muvalaplin in patients with elevated Lp(a) and atherosclerotic cardiovascular disease (ASCVD) have been published.

Lowering LDL-C does not fully offset ASCVD risk of elevated Lp(a)

December 18, 2024

Lp(a) and LDL-C have independent and additive adverse effects on risk of atherosclerotic cardiovascular disease (ASCVD), and lowering LDL-C does not fully offset Lp(a)-mediated risk, according to the results of a meta-analysis of data from 27,658 participants enrolled in six placebo-controlled statin trials (4D, 4S, CARDS, JUPITER, LIPID, MIRACL). The studies assessed the association of […]

More evidence of intraindividual Lp(a) variability

December 11, 2024

Analysis of placebo-treated patients in the Phase 2 OCEAN(a)-DOSE trial of olpasiran in patients with Lp(a) concentration >150 nmol/L and established atherosclerotic cardiovascular disease (ASCVD) has shown notable intraindividual variability in serial Lp(a) concentration during follow-up.

Is Lp(a) lower with high TG?

November 25, 2024

Patients with severe hypertriglyceridaemia (sHTG) (≥ 10 mmol/L) have lower plasma Lp(a) than those with normal lipid levels, irrespective of the cause of sHTG. This is the finding from a retrospective chart review of patients attending a lipid genetics clinic in Canada.

Should Lp(a) levels be measured more than once?

October 16, 2024

Variations in Lp(a) levels with time, recorded in a third of clinically stable patients attending a lipid clinic in Argentina, suggest that repeat measurements may be needed, especially in those with borderline elevated Lp(a) levels. This was the conclusion of Dr Pablo Corral and colleagues who carried out a retrospective analysis of Lp(a) levels in […]

New insights on Lp(a) testing around the world

October 9, 2024

Recently published results of Lp(a) studies in Japan, Pakistan and Poland are helping to build a more detailed picture of Lp(a) levels worldwide, together with broader insights on testing practices.